← Therapy pipeline
Investigational · Obesity development

Ribupatide injection

KAI-9531 · HRS9531 · Ribupatide · Kailera Therapeutics

Global Phase 3 is underway; U.S. high-dose Phase 2b results are expected in mid-2027.

GLP-1GIP
Other study areas
Type 2 diabetes
Selected program areas, not approvals. See the full profile for individual trials.
Obesity stagePhase 3Updated as of November 2026
SponsorKailera Therapeutics
TargetsGLP-1 + GIP
RouteInjection
DevelopmentObesity-specific
01 / Evidence

Selected study results

GEMINI-1 · ChinaMean body-weight changeBody weight decreased 17.7% · 48 weeks · Phase 3
Phase 3 · Injection · Peer-reviewed results

Mean body-weight change · 48 weeks

Study focus: Weight management

GEMINI-1: randomized, double-blind, placebo-controlled Phase 3 trial at 55 sites in China.

Investigational regimen
17.7%
Placebo / comparator
1.4%

Adults with overweight or obesity in China without diabetes · 6 mg weekly vs placebo · Trial N=567 · Primary treatment-policy estimand. Results & methods ↗ · Publication ↗

Gastrointestinal adverse events occurred in 63.1% with 6 mg and 23.1% with placebo, mostly mild to moderate. These China results are separate from the global KaiNETIC program.

Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIPTargeted
GCGglucagon—
AMYamylin—
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

InjectionOnce weekly
Phase 3Global KaiNETIC Phase 3 active; China Phase 3 results reported
Milestone → next

Latest: Enrollment complete across KaiNETIC-1, -2 and -3; sponsor expects topline results in mid-2028.

Next: KaiNETIC topline results expected mid-2028.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 3 studies4 records

Phase 3

GEMINI-1 · China

Weight management · China
Study: CompletedResults: Peer-reviewed results shown aboveStatus reviewed November 2026

567 adults without diabetes in China; ribupatide 2, 4 or 6 mg weekly versus placebo for 48 weeks. Primary treatment-policy results published in JAMA.

Phase 3

KaiNETIC-1

Weight management
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Global chronic weight-management study in adults with obesity or overweight without type 2 diabetes. Enrollment complete per September 30 sponsor announcement; topline expected mid-2028.

Phase 3

KaiNETIC-2

Weight management with type 2 diabetes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Global chronic weight-management study in adults with obesity or overweight and type 2 diabetes. Enrollment complete per September 30 sponsor announcement; topline expected mid-2028.

Phase 3

KaiNETIC-3

Comparative weight management
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Global chronic weight-management study in adults with BMI at least 35 without type 2 diabetes; semaglutide comparator. Enrollment complete per September 30 sponsor announcement; topline expected mid-2028.

Phase 2 studies1 record

Phase 2b

U.S. high-dose Phase 2b study

Weight management
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

48-week dose-ranging injectable study; separate from the global Phase 3 KaiNETIC studies.